Integrated positron emission tomography/computed tomography (PET/CT) with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of (18)F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. (18)F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.
Japanese journal of radiology. 2016 May 24 [Epub ahead of print]
Kazuhiro Kitajima, Shingo Yamamoto, Kazuhito Fukushima, Ryogo Minamimoto, Takao Kamai, Hossein Jadvar
Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medical Center, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. ., Department of Urology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan., Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medical Center, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan., Department of Radiology, Division of Nuclear Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan., Department of Urology, Dokkyo Medical University School of Medicine, 880 Kita-kobayashi, Mibu, Tochigi, 321-0293, Japan., Department of Radiology, Division of Nuclear Medicine, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA, 90033, USA.